Zobrazeno 1 - 10
of 107
pro vyhledávání: '"M Benmebarek"'
Autor:
S Stock, M Benmebarek, A Kluever, D Darowski, C Jost, K Stubenrauch, J Benz, A Freimoser-Grundschober, E Moessner, P Umana, M Subklewe, S Endres, C Klein, S Kobold
Publikováno v:
Poster Presentations.
Autor:
M Benmebarek, F Märkl, J Keyl, B Cadilha, M Geiger, C Karches, H Obeck, M Schwerdtfeger, D Briukhovetska, J Jobst, PJ Müller, M Seifert, R Grünmeier, M Thomas, C Marr, M Levesque, M Heppt, S Endres, C Klein, S Kobold
Publikováno v:
Oral Presentations.
Autor:
A Gottschlich, M Thomas, R Grünmeier, S Lesch, L Rohrbacher, V Igl, D Briukhovetska, M Benmebarek, S Dede, K Müller, T Xu, D Dhoqina, Ö Umut, F Märkl, S Robinson, A Sendelhofert, H Schulz, B Vick, BL Cadilha, R Brabenec, N Röder, F Rataj, M Nüesch, J Wellbrock, F Modemann, W Fiedler, C Kellner, T Herold, D Paquet, I Jeremias, L von Baumgarten, S Endres, M Subklewe, C Marr, S Kobold
Publikováno v:
Poster Presentations.
Autor:
A Öner, Bruno L. Cadilha, C. Karches, Stefan Endres, Martina Geiger, M. Benmebarek, Sebastian Kobold, F Märkl, Christian Klein, Melanie Schwerdtfeger, Vincenzo Desiderio
Publikováno v:
Poster Presentations.
Background Chimeric antigen receptor therapy – although very efficacious in B cell malignancies – is facing many challenges which limit its success in solid tumors, e.g. on-target off-tumor toxicities, antigen heterogeneity, lack of T cell migrat
Autor:
Abbass Darwich, Saskia Schmitt, Bettina Brauchle, S Stoiber, Christian Augsberger, Stefan Endres, S Lesch, Sebastian Kobold, Rataj, Christian Klein, B Loureiro Cadilha, Nadja C. Fenn, Marion Subklewe, M Benmebarek, Monika Herrmann, M Schwerdtfeger, Karl-Peter Hopfner, A Gottschlich
Publikováno v:
Poster Presentations.
Background Targeted immunotherapies have shown limited success in the context of acute myeloid leukemia (AML). The mutational landscape, heterogeneity attributed to this malignancy and toxicities associated with the targeting of myeloid lineage antig
Autor:
M Seifert, M Benmebarek, B Cadilha, J Jobst, J Dörr, T Lorenzini, D Dhoqina, J Zhang, U Schindler, S Endres, S Kobold
Publikováno v:
Poster Presentations.
Background Despite remarkable response rates mediated by anti-CD19 chimeric antigen receptor (CAR) T cells in selected B cell malignancies, CAR T cell therapy still lacks efficacy in the vast majority of tumors. A substantial limiting factor of CAR T
Autor:
Maria Rescigno, Abbass Darwich, Hannah Obeck, Claudio Sustmann, Alexandre Taleb, Giuseppe Curigliano, Giovanna Masci, Lapo Morelli, Sebastian Kobold, M. Benmebarek, Alessia Melacarne, Domenico Supino, Alessandra Silvestri, Agnese Losurdo, Giuseppe Penna, Bruno L. Cadilha, Juliette Mouriès
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for the Immunotherapy of Cancer
Journal for the Immunotherapy of Cancer
BackgroundNatural killer (NK) cells require a functional lytic granule machinery to mediate effective antitumor responses. Evading the lytic cargo deployed at the immune synapse (IS) could be a critical step for cancer progression through yet unident
Autor:
M Benmebarek, F Märkl, J Keyl, B Loureiro Cadilha, M Geiger, C Karches, S Endres, C Klein, S Kobold, A Klüver, M Schwerdtfeger
Publikováno v:
Poster Presentations.
Autor:
J Dörr, Bruno L. Cadilha, C. Karches, J. Keyl, Sebastian Kobold, Martina Geiger, F Märkl, A Öner, Adrian Gottschlich, S Rausch, M Feinendegen, M. Benmebarek, Christian Klein, Stefan Endres
Publikováno v:
E-Poster Presentations.
Background Immunotherapeutic approaches, including immune checkpoint blockade and adoptive T cell therapy (ACT) in the form of tumor-infiltrating lymphocytes (TILs), have had marked success in the treatment of melanoma. Despite these successes, many
Autor:
Christine Hörth, A Nottebrock, M. Benmebarek, Justyna Ogonek, Stefanie Lesch, Philipp Metzger, Sebastian Kobold, Stefan Endres, S Stoiber, Bruno L. Cadilha, Adrian Gottschlich
Publikováno v:
E-Poster Presentations.
Background Chimeric antigen receptor (CAR) T cell therapy is currently approved for the treatment of some hematological malignancies. However, CAR T cells have so far lacked efficacy in the treatment of solid tumors. A major hurdle of CAR T cell ther